Table 4.

COVID-19-related hospitalization rate after the first and second doses of vaccinated patients.

First author	Vaccine type	Country	Type of study	Group of study	SARS-COV 2 incidence
					Partial vaccinated		Unvaccinated		Odds ratio*	Full vaccinated		Unvaccinated		Odds ratio*
					Cases	Total	Cases	Total		Cases	Total	Cases	Total
Iván Martínez-Baz (56)	BNT162b2 mRNA	Spain	Prospective cohort study	Aged ≥18 year	6	2,022	214	14,348	0.197	20	7,972	214	14,348	0.166
Wesley H. Self (72)	BNT162b2 mRNA	USA	Case–control study	Among Adults	-	-	-	-	-	128	738	1,463	2,362	0.129
Jamie Lopez Bernal (59)	BNT162b2 mRNA	UK	Case–control study	Age ≥70 years,	128	1,400	1,365	8,892	0.555	-	-	-	-	-
M.G. Thompson (20)	BNT162b2 mRNA	USA	Case–control study	Aged ≥50 years	140	1,444	3,695	20,406	0.486	220	9,848	3,695	20,406	0.103
Iván Martínez-Baz (56)	mRNA-1273	Spain	Prospective cohort study	Aged ≥18 year	2	517	214	14,348	0.256	1	1,127	214	14,348	0.059
M.G. Thompson (20)	mRNA-1273	USA	Case–control study	Aged ≥50 years	91	1,639	3,695	20,406	0.266	145	7,508	3,695	20,406	0.089
Iván Martínez-Baz (56)	ChAdOx1	Spain	Prospective cohort study	Aged ≥18 year	8	1,599	214	14,348	0.332	2	1,539	214	14,348	0.086
Jamie Lopez Bernal (59)	ChAdOx1	UK	Case–control study	Adult age ≥70	9	126	1,365	8,892	0.424	-	-	-	-	-
Anoop S. V. Shah (66)	Combination†	Scotland	Prospective cohort study	Healthcare workers	19	1,11,081	158	1,44,525	0.156	-	-	-	-	-
Jennifer B. Griffin (73)	Combination†	USA	Prospective cohort study	Aged ≥16 years	29	1,431	1,289	30,801	0.474	136	10,895	1,289	30,801	0.289

^*Rate Ratio computed.

^†BNT162b2 mRNA and mRNA-1273 and ChAdOx1.